BRPI0807597A2 - Composição farmacêutica, e, método para tratar infecção por vírus da influenza - Google Patents

Composição farmacêutica, e, método para tratar infecção por vírus da influenza

Info

Publication number: BRPI0807597A2
Authority: BR; Brazil
Prior art keywords: pharmaceutical composition; influenza virus; virus infection; treating influenza; treating
Prior art date: 2007-02-16

Application number

BRPI0807597-2A2A

Other languages

English (en)

Inventor

Masako Maekawa

Original Assignee

Toyama Chemical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-16

Filing date

2008-02-14

Publication date

2014-05-06

2008-02-14 Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd

2014-05-06 Publication of BRPI0807597A2 publication Critical patent/BRPI0807597A2/pt

2021-03-02 Publication of BRPI0807597B1 publication Critical patent/BRPI0807597B1/pt

2021-05-25 Publication of BRPI0807597B8 publication Critical patent/BRPI0807597B8/pt

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
241000712461 unidentified influenza virus Species 0.000 title 1
230000009385 viral infection Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0807597A 2007-02-16 2008-02-14 composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação BRPI0807597B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2007035975		2007-02-16
JP2007-035975		2007-12-27
PCT/JP2008/052425 WO2008099874A1 (ja)	2007-02-16	2008-02-14	ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法

Publications (3)

Publication Number	Publication Date
BRPI0807597A2 true BRPI0807597A2 (pt)	2014-05-06
BRPI0807597B1 BRPI0807597B1 (pt)	2021-03-02
BRPI0807597B8 BRPI0807597B8 (pt)	2021-05-25

Family

ID=39690101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0807597A BRPI0807597B8 (pt)	2007-02-16	2008-02-14	composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação

Country Status (21)

Country	Link
US (1)	US8759354B2 (pt)
EP (1)	EP2123276B1 (pt)
JP (1)	JP5255456B2 (pt)
KR (1)	KR101479083B1 (pt)
CN (1)	CN101610772B (pt)
AU (1)	AU2008215397B2 (pt)
BR (1)	BRPI0807597B8 (pt)
CA (1)	CA2677905C (pt)
CY (1)	CY1113435T1 (pt)
DK (1)	DK2123276T3 (pt)
ES (1)	ES2396595T3 (pt)
HR (1)	HRP20130111T1 (pt)
IL (1)	IL200285A (pt)
MX (1)	MX2009008779A (pt)
NZ (1)	NZ578989A (pt)
PL (1)	PL2123276T3 (pt)
PT (1)	PT2123276E (pt)
RU (1)	RU2463051C2 (pt)
SI (1)	SI2123276T1 (pt)
WO (1)	WO2008099874A1 (pt)
ZA (1)	ZA200905536B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010117114A1 (en) *	2009-04-09	2010-10-14	Lg Electronics Inc.	Display apparatus
CN103068378B (zh) *	2010-05-10	2016-07-06	中央研究院	具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
MY161757A (en)	2010-09-30	2017-05-15	Toyama Chemical Co Ltd	Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
SG189161A1 (en) *	2010-09-30	2013-05-31	Toyama Chemical Co Ltd	Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
AT510585B1 (de) *	2010-11-18	2012-05-15	Apeptico Forschung & Entwicklung Gmbh	Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
AU2014265483B2 (en) *	2013-05-14	2018-08-02	Biocryst Pharmaceuticals, Inc.	Anti-influenza compositions and methods
CN104447583B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	吡嗪类化合物及其组合物及用途
CN104402833B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) *	2014-12-10	2016-08-24	广东东阳光药业有限公司	吡嗪衍生物及其用途
CN104817511B (zh) *	2015-04-27	2017-04-19	济南大学	一种丁烯二酸酐制备法匹拉韦关键中间体的方法
SG10201911957QA (en) *	2015-12-15	2020-02-27	Shionogi & Co	Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP7369143B2 (ja)	2018-12-25	2023-10-25	富士フイルム富山化学株式会社	ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤
US20230210848A1 (en) *	2020-04-30	2023-07-06	Fujifilm Toyama Chemical Co., Ltd.	Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
EP4159215A4 (en)	2020-05-27	2023-11-22	FUJIFILM Toyama Chemical Co., Ltd.	THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINATION OF A PYRAZINE DERIVATIVE AND A THIOPURINE DERIVATIVE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01197437A (ja) *	1988-01-29	1989-08-09	Dso Pharmachim	抗ウイルス薬
TR200100574T2 (tr) *	1998-08-20	2001-07-23	Toyama Chemical Co., Ltd.	Nitrojenöz heteroksiklik karboksamid türevlerini içeren antiviral ajanlar
KR100894167B1 (ko)	2001-08-14	2009-04-22	토야마 케미칼 컴퍼니 리미티드	신규의 바이러스 증식저해 ·살바이러스방법 및 신규의피라진뉴클레오티드 ·피라진뉴클레오시드 유사체
JP2005354833A (ja) *	2004-06-11	2005-12-22	Fujinon Corp	アクチュエータ
JP4689989B2 (ja) *	2004-08-27	2011-06-01	オリンパス株式会社	振動波リニアモータ及びそれを用いたレンズ装置
DE102008031715A1 (de)	2008-07-04	2010-01-07	Henkel Ag & Co. Kgaa	Haarkonditionierende Mittel mit Imidazolinen

2008
- 2008-02-14 CA CA2677905A patent/CA2677905C/en active Active
- 2008-02-14 PL PL08711267T patent/PL2123276T3/pl unknown
- 2008-02-14 PT PT87112678T patent/PT2123276E/pt unknown
- 2008-02-14 HR HRP20130111AT patent/HRP20130111T1/hr unknown
- 2008-02-14 CN CN200880005061XA patent/CN101610772B/zh active Active
- 2008-02-14 SI SI200830895T patent/SI2123276T1/sl unknown
- 2008-02-14 WO PCT/JP2008/052425 patent/WO2008099874A1/ja not_active Ceased
- 2008-02-14 JP JP2008558114A patent/JP5255456B2/ja active Active
- 2008-02-14 US US12/527,260 patent/US8759354B2/en active Active
- 2008-02-14 MX MX2009008779A patent/MX2009008779A/es active IP Right Grant
- 2008-02-14 ZA ZA200905536A patent/ZA200905536B/xx unknown
- 2008-02-14 BR BRPI0807597A patent/BRPI0807597B8/pt active IP Right Grant
- 2008-02-14 NZ NZ578989A patent/NZ578989A/en unknown
- 2008-02-14 EP EP08711267A patent/EP2123276B1/en active Active
- 2008-02-14 ES ES08711267T patent/ES2396595T3/es active Active
- 2008-02-14 RU RU2009134516/15A patent/RU2463051C2/ru active
- 2008-02-14 KR KR20097017506A patent/KR101479083B1/ko active Active
- 2008-02-14 AU AU2008215397A patent/AU2008215397B2/en active Active
- 2008-02-14 DK DK08711267.8T patent/DK2123276T3/da active
2009
- 2009-08-06 IL IL200285A patent/IL200285A/en not_active IP Right Cessation
2012
- 2012-12-03 CY CY20121101175T patent/CY1113435T1/el unknown

Also Published As

Publication number	Publication date
JP5255456B2 (ja)	2013-08-07
EP2123276B1 (en)	2012-11-28
RU2009134516A (ru)	2011-03-27
ES2396595T3 (es)	2013-02-22
RU2463051C2 (ru)	2012-10-10
AU2008215397A1 (en)	2008-08-21
DK2123276T3 (da)	2013-01-02
PL2123276T3 (pl)	2013-04-30
HRP20130111T1 (hr)	2013-02-28
BRPI0807597B8 (pt)	2021-05-25
CA2677905C (en)	2015-03-24
KR20090121289A (ko)	2009-11-25
AU2008215397B2 (en)	2012-09-06
US8759354B2 (en)	2014-06-24
BRPI0807597B1 (pt)	2021-03-02
CN101610772A (zh)	2009-12-23
PT2123276E (pt)	2013-01-16
WO2008099874A1 (ja)	2008-08-21
CA2677905A1 (en)	2008-08-21
JPWO2008099874A1 (ja)	2010-05-27
CY1113435T1 (el)	2016-06-22
ZA200905536B (en)	2010-10-27
US20100087447A1 (en)	2010-04-08
IL200285A (en)	2014-06-30
SI2123276T1 (sl)	2013-03-29
MX2009008779A (es)	2009-11-05
NZ578989A (en)	2011-07-29
KR101479083B1 (ko)	2015-01-07
CN101610772B (zh)	2013-01-16
IL200285A0 (en)	2010-04-29
EP2123276A4 (en)	2011-05-18
EP2123276A1 (en)	2009-11-25

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-30	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B25A	Requested transfer of rights approved	Owner name: FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP)
2019-10-15	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-06-09	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-06-30	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-11-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-12-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-03-02	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0807597A2 (pt)	2014-05-06	Composição farmacêutica, e, método para tratar infecção por vírus da influenza
BRPI0815057A2 (pt)	2015-07-28	Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0916235A2 (pt)	2018-03-13	composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI0814939A2 (pt)	2015-01-27	Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
BRPI0814300A2 (pt)	2015-02-03	Composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI1013394A2 (pt)	2016-06-21	"composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
BRPI0820578A2 (pt)	2015-06-16	Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças
BRPI1014322A2 (pt)	2015-08-25	Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
BRPI1013640A2 (pt)	2019-09-24	composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BRPI0906804A2 (pt)	2015-07-14	Método para liofilizar partículas, e, acondicionamento farmacêutico
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BR112013015010A2 (pt)	2016-08-09	produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0811589A2 (pt)	2014-10-29	Composição farmacêutica e método para tratar câncer
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
EP2497482A4 (en)	2013-05-01	COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUSED INDUCED DISEASES
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
IL202450A (en)	2015-05-31	Pharmaceutical composition to treat influenza virus infection
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.